Charles Ryan: Hello from PCF 2019. I’m joined today by Dr. Justin Drake from the University of Minnesota where he is an Assistant Professor in the Departments of Urology and Pharmacology. Justin is one of my colleagues and we have a mutual interest in neuroendocrine prostate cancer. And you have your own space that you’re […]
Several models are adopted in clinical practice to estimate prognosis of patients with metastatic renal cell carcinoma (mRCC); however, none of these models have evaluated patients treated by immune-checkpoint inhibitors.
8p deletions are common in renal cell carcinoma. To study their prognostic impact and association with kidney cancer phenotype, a tissue microarray with 1,809 cancers was analyzed by fluorescence in situ hybridization for 8p21 copy numbers.
The complexity of bladder cancer diagnosis and staging results in delays in definitive treatment of muscle-invasive bladder cancer by radical cystectomy. This systematic review and meta-analyses aim to assess the impact of delays in radical cystectomy.
This article provides a comprehensive review of the available data for immunotherapy being used as a salvage treatment in non-muscle-invasive bladder cancer. The literature demonstrates that the immune system has an important role in bladder cancer progression.
The best predictors of response to intravesical immunotherapy are tumor grade and stage, tumor recurrence pattern, nomograms, panels of urinary cytokines, and fluorescent in situ hybridization patterns of urine cytology examinations.
To study if prostatic ductal adenocarcinoma (PDA) controlled by Grade Group (GG), PSA, and tumor volume (TV) is an independent predictor of adverse radical prostatectomy (RP) outcomes. One-hundred-and-twenty-eight PDA and 1,141 acinar continuous RPs were studied.
The aim of this study was to describe age- related prostate cancer (PCa) characteristics in men after radical prostatectomy (RP). There were 2,373 men who underwent RP for clinically localized PCa between 2002 and 2017 and had complete data that were included into the study.
To review available prostate cancer biomarkers and their performance in a clinical order, from prostate cancer detection, to treatment of localized and advanced disease. We used an electronic literature search of the PubMed database using the key words "prostate biomarkers," "genomic markers," and "prostate cancer screening," as well as specific biomarkers, until March 2019.
Active surveillance (AS) is an increasingly utilized strategy for monitoring men with low-risk prostate cancer (PCa) that allows them to defer active treatment (AT) in the absence of cancer progression.
